Arterial plaque can be reduced, and in some cases partially reversed, through a combination of aggressive cholesterol lowering, diet changes, exercise, and targeted medications. The key driver is getting LDL cholesterol low enough for long enough. Every 1% reduction in plaque volume is associated with a 20% drop in the odds of a major cardiovascular event like a heart attack or stroke, so even modest shrinkage matters.
Plaque builds up when cholesterol particles penetrate damaged artery walls, triggering inflammation. Immune cells swallow the cholesterol and form fatty deposits. Over time, smooth muscle cells create a fibrous cap over the deposit, producing a mature plaque. Reversing this process means pulling fat out of the plaque, calming inflammation, and thickening that protective cap so it’s less likely to rupture.
How Low Your Cholesterol Needs to Go
The single most powerful lever for shrinking plaque is lowering LDL cholesterol, and the targets are more aggressive than many people realize. The 2026 guidelines from the American College of Cardiology and American Heart Association set specific goals based on how much plaque you already have. If you’ve had a heart attack or have established heart disease, the target is an LDL below 55 mg/dL. If imaging shows significant calcium buildup in your coronary arteries (a score of 300 or higher), the same 55 mg/dL goal applies, along with at least a 50% reduction from your starting level.
For people with moderate calcium scores (100 to 299), the goal is an LDL below 70 mg/dL. Even people with mild coronary calcium (scores of 1 to 99) are now recommended to get below 100 mg/dL. These numbers are lower than previous guidelines suggested, reflecting strong evidence that plaque regression scales with how far you push LDL down.
Statins remain the first-line treatment and produce plaque regression in a dose-dependent way: the bigger the LDL drop, the more plaque shrinks. In imaging studies, high-intensity statin therapy reduces percent atheroma volume by roughly 0.7% to 1.5%, depending on starting plaque burden. That may sound small, but it represents a meaningful structural change inside the artery wall. Statins also reshape plaque composition in a favorable direction. The soft, fatty core shrinks while the fibrous cap thickens, making the plaque more stable and less prone to the ruptures that cause heart attacks.
When statins alone aren’t enough, adding other cholesterol-lowering medications pushes LDL further down. PCSK9 inhibitors, injectable drugs given every two to four weeks, produce additional plaque benefits on top of statins. A meta-analysis of seven trials covering nearly 1,750 patients found that adding a PCSK9 inhibitor to statin therapy significantly reduced total plaque volume and increased fibrous cap thickness by about 29 micrometers more than statins alone. That thicker cap is a critical safety margin.
The Mediterranean Diet Effect
Diet changes can directly affect the artery wall, not just your cholesterol numbers. The strongest evidence comes from the PREDIMED trial, which tested a Mediterranean diet supplemented with either extra virgin olive oil or about an ounce of mixed nuts daily, compared to a standard low-fat diet. After an average of 2.4 years, the group eating a Mediterranean diet with nuts showed actual regression in carotid artery wall thickness, while the low-fat diet group saw their arteries get thicker.
The numbers were striking. The nut-supplemented Mediterranean group saw a decrease of 0.084 mm in artery wall thickness, while the control group progressed by 0.052 mm in the wrong direction. Plaque height also shrank in the nut group and grew in the control group. Interestingly, the olive oil version of the Mediterranean diet didn’t produce the same measurable changes in artery wall thickness, though the overall PREDIMED trial still showed cardiovascular benefit from both versions.
The practical takeaway: a diet rich in vegetables, legumes, fish, whole grains, and nuts, with olive oil as the primary fat source, does more than lower your risk on paper. It appears to change what’s happening inside artery walls.
How Exercise Changes Plaque
Exercise reduces plaque lipid content regardless of intensity. A study of 60 patients with stable coronary artery disease compared supervised high-intensity interval training (hitting 85% to 95% of peak heart rate) against standard unsupervised endurance exercise. After six months, both groups showed similar 13% to 14% reductions in coronary plaque lipid content. The high-intensity group got significantly fitter, improving their cardiorespiratory capacity by 12% compared to 5% in the standard group, but the plaque benefits were equivalent.
What mattered most wasn’t the type of exercise but the improvement in fitness. When researchers combined both groups, they found a clear correlation: the more someone’s fitness improved, the more their plaque lipid content decreased. This suggests that consistency matters more than intensity. Whatever form of exercise you’ll actually stick with for months is the one most likely to benefit your arteries.
High-Dose EPA for Plaque Reduction
A purified, prescription-strength omega-3 fatty acid called icosapent ethyl has shown remarkable effects on plaque in people with elevated triglycerides already taking statins. The EVAPORATE trial found that 4 grams daily reduced total plaque volume by 9% over 18 months, while the placebo group saw an 11% increase. The most dangerous type of plaque, the soft low-attenuation kind most likely to rupture, decreased by 17% with treatment but more than doubled in the placebo group.
This is not the same as taking fish oil capsules from a drugstore. Standard fish oil supplements contain a mix of EPA and DHA and have not shown the same plaque or cardiovascular benefits. The effect appears specific to high-dose purified EPA, which is available by prescription for people with elevated triglycerides (generally above 150 mg/dL) despite statin use.
Targeting Inflammation Directly
Plaque isn’t just a cholesterol problem. It’s an inflammatory problem. Even after cholesterol is optimized, residual inflammation keeps plaque unstable. Colchicine, a decades-old anti-inflammatory drug traditionally used for gout, has emerged as a tool for stabilizing coronary plaque. In the COLOCT trial, patients who had recently experienced an acute coronary event and received colchicine saw their fibrous cap thickness nearly double compared to placebo (increasing from about 52 to 87 micrometers). The drug also reduced the inflammatory cells embedded in plaque.
This matters because most heart attacks happen when a thin-capped plaque ruptures, exposing its contents to the bloodstream and triggering a clot. Making that cap thicker is protective even if the plaque doesn’t shrink. Colchicine is now used in some patients with established heart disease specifically for this purpose.
What Plaque Stabilization Looks Like
It’s worth understanding that “reducing plaque” doesn’t always mean making it disappear. In many cases, the more important change is transforming dangerous plaque into stable plaque. Dangerous plaques have large pools of soft fat, thin fibrous caps, and heavy infiltration by inflammatory cells. Stable plaques are denser, more calcified, with thick caps and less inflammatory activity.
Statins actually increase the calcified and fibrous components of plaque while shrinking the fatty, necrotic core. Your calcium score on a CT scan might go up even as your actual cardiovascular risk drops. This is a common source of confusion. A higher calcium score after starting treatment doesn’t mean things are getting worse. It often means soft, rupture-prone plaque is being converted into hard, stable plaque that’s far less likely to cause a heart attack.
Putting It Together
Plaque reduction works best as a multi-front strategy. Cholesterol lowering does the heavy lifting, and getting LDL below 55 to 70 mg/dL (depending on your risk level) is the most evidence-backed step. A Mediterranean-style diet rich in nuts, fish, and olive oil provides additional benefit beyond what cholesterol numbers alone would predict. Regular exercise, sustained over months, reduces plaque lipid content through improved fitness. For people with elevated triglycerides, prescription-strength EPA offers a meaningful additional layer. And for those with established heart disease, anti-inflammatory therapy can stabilize the plaques that remain.
The timeline for measurable change is generally six months to two years, based on the imaging studies that have tracked plaque regression. The process is gradual, but the artery wall is not static. Given the right conditions, your body can pull cholesterol back out of plaque, recruit cleanup cells, and rebuild a thicker, stronger cap over what remains.